Managed care stocks diverge in 2025: ALHC and OSCR rise while UNH, CNC slide
Seeking Alpha News (Fri, 19-Dec 6:50 AM ET)
Clover Health to Participate in Upcoming J.P. Morgan 2026 Healthcare Conference
Globe Newswire (Tue, 16-Dec 4:05 PM ET)
From Hype to P&L: Hospitals Now Buying AI That Pays
Globe Newswire (Mon, 8-Dec 1:18 PM ET)
Clover Health to Participate in Upcoming 2025 Citi Global Healthcare Conference
Globe Newswire (Mon, 17-Nov 4:05 PM ET)
Clover Health Reports Third Quarter 2025 Results
Globe Newswire (Tue, 4-Nov 4:05 PM ET)
Clover Health Announces Chelsea Clinton to Step Down from Board Following Eight Years of Service
Globe Newswire (Fri, 31-Oct 4:05 PM ET)
Globe Newswire (Thu, 30-Oct 4:30 PM ET)
Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference
Globe Newswire (Wed, 22-Oct 4:30 PM ET)
Clover Health's 2026 Medicare Advantage Plans Champion Affordability and Choice
Globe Newswire (Wed, 15-Oct 8:30 AM ET)
Counterpart Health Expands Proven Flywheel for HEDIS Excellence to Third-Party Partners
Globe Newswire (Tue, 14-Oct 8:30 AM ET)
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Clover Health Investments Corp. - Class A trades on the NASDAQ stock market under the symbol CLOV.
As of December 19, 2025, CLOV stock price was flat at $2.58 with 5,417,718 million shares trading.
CLOV has a beta of 1.11, meaning it tends to be more sensitive to market movements. CLOV has a correlation of 0.07 to the broad based SPY ETF.
CLOV has a market cap of $1.33 billion. This is considered a Small Cap stock.
Last quarter Clover Health Investments Corp. - Class A reported $497 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $24 million and missed earnings estimates by -$.04.
In the last 3 years, CLOV traded as high as $4.87 and as low as $.61.
The top ETF exchange traded funds that CLOV belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
CLOV has underperformed the market in the last year with a price return of -18.1% while the SPY ETF gained +17.3%. CLOV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.0% and -3.0%, respectively, while the SPY returned +3.3% and -0.6%, respectively.
CLOV support price is $2.49 and resistance is $2.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLOV shares will trade within this expected range on the day.